Sign in

BCTX on Nasdaq

BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a Canadian pharmaceutical preparations company based in West Vancouver.2 Its shares trade on Nasdaq under the symbol BCTX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

-$26.3MNet income, fiscal 20253

Compare with another stock.

  • TickerBCTX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWest Vancouver, Canada2
  • Incorporated inBritish Columbia, Canada4
  • Business address3Rd Floor, Bellevue Centre, 235-15Th Str, West Vancouver, A1 V7T 2X14
  • Filer category, Emerging growth company4
  • Legal formCompany (includes community contribution company and unlimited liability company)2
  • LEI529900NQNTTXYE8742832
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered address3rd Floor. Bellevue Centre, 235-15th Street, V7T 2X1 West Vancouver, Canada2
  • Registered withBC Registry Services, BC07645472

See how the biggest companies compare on our leaderboards

New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ for prostate cancer.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-151.8%Return on equity3

Financial statements

Operating income67893-$27.2M in 2025+591% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$3.9M-$3.9M20202021: -$7.0M-$7.0M2021+77%2022: -$15.3M-$15.3M2022+119%2023: -$23.3M-$23.3M2023+52%2024: -$33.3M-$33.3M2024+43%2025: -$27.2M-$27.2M2025−18%
Net income67893-$26.3M in 2025+458% since 2019
-$30.0M-$20.0M-$10.0M02019: -$4.7M-$4.7M20192020: -$4.0M-$4.0M2020−15%2021: -$13.8M-$13.8M2021+243%2022: -$26.8M-$26.8M2022+94%2023: -$20.3M-$20.3M2023−24%2024: -$4.8M-$4.8M2024−76%2025: -$26.3M-$26.3M2025+449%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-07-312024-07-31
Research and development expenses$21.3M$27.2M
General and administrative expenses$5.9M$6.2M
Total operating expenses$27.2M$33.3M
Operating loss-$27.2M-$33.3M
Financial income (expenses), net$114.5K$262.6K
Change in fair value of the warrant liability$758.4K$28.2M
Share of loss on equity investment-$224.2K-$106.5K
Net loss for the year-$26.6M-$4.9M
Net loss attributable to non-controlling interest-$244.3K-$140.1K
Net loss for the year attributable to BriaCell-$26.3M-$4.8M
Net loss per share attributable to BriaCell - basic-$62.19-$43.68
Net loss per share attributable to BriaCell - diluted-$62.19-$43.68
Weighted average number of shares (*) used in computing net loss per share attributable to ordinary shareholders, basic423.1K shares109.7K shares
Weighted average number of shares (*) used in computing net loss per share attributable to ordinary shareholders, diluted423.1K shares109.7K shares

Compare BriaCell Therapeutics Corp. with another company

Corporate structure

BriaCell Therapeutics Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BriaCell Therapeutics Corp.

  • BriaCell Therapeutics Corp. West Vancouver, British Columbia, Canada

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BriaCell Therapeutics Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$456.8K3 Jul 31, 2024
Property and equipment, net$296.8K3 Jul 31, 2025$388.2K3 Jul 31, 2024−23.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$10.5M3 Jul 31, 2025$862.1K3 Jul 31, 2024+1117.3%
Marketable securities, current$7.4M3 Jul 31, 2025

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$184.5K3 Jul 31, 2025$199.8K3 Jul 31, 2024−7.6%
Finite-lived intangibles, gross$305.1K3 Jul 31, 2025$305.1K3 Jul 31, 20240%
Accumulated amortization$120.6K3 Jul 31, 2025$105.3K3 Jul 31, 2024+14.5%
Finite-lived intangibles, net$184.5K3 Jul 31, 2025$199.8K3 Jul 31, 2024−7.6%
Patents, net$305.1K3 Jul 31, 2025$305.1K3 Jul 31, 20240%

Properties, in its own words

As of August 2025, the Company commenced a month-to-month lease arrangement for office and lab space in Philadelphia, Pennsylvania, in the amount of approximately $43,000 per month. The Company also maintains office space in West Vancouver, British Columbia Canada.

Item 2 of the 10-K filed Oct 16, 2025.5

Leadership

Who has led BriaCell Therapeutics Corp., and when. Pick a name to see everywhere that person has worked.

Chair

  1. Jamieson Bondarenko2022

Chief financial officer

  1. Gadi Levin2022
2025
Board members and other officers (7)

Former names

  • Ansell Capital Corp.Jun 20, 2014 to Jun 20, 20144

Timeline

  1. Jun 26, 20268-K Regulation FD disclosure22
  2. Jun 3, 20268-K Entered a material agreement; Unregistered sale of shares; Other events23
  3. Mar 31, 20268-K Regulation FD disclosure24
  4. Mar 9, 20268-K Shareholder vote25
  5. Feb 20, 20268-K Other events26
  6. Jan 15, 20268-K Entered a material agreement; Other events27
  7. Dec 29, 20258-K Regulation FD disclosure28
  8. Dec 1, 20258-K Regulation FD disclosure29
  9. Aug 26, 20258-K Other events30
  10. Jul 16, 20258-K Entered a material agreement; Other events31
  11. Jun 18, 20258-K Regulation FD disclosure32
  12. Apr 28, 20258-K Entered a material agreement; Other events33

Calendar

Coming up

  1. Oct 21, 2026Reports results for the quarter ending Jul/202634

When it reported results

  1. Oct 28, 2022Reported quarterly or annual results35

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

230 filings to the SEC since October 2021: 6 annual reports, 12 quarterly reports, 65 major events, 14 insider forms, 27 large holders, 106 other. The latest 20:

  1. Jun 26, 20268-K EDGAR
  2. Jun 9, 202610-Q EDGAR
  3. Jun 3, 20268-K EDGAR
  4. Jun 2, 2026424B5 EDGAR
  5. Mar 31, 20268-K EDGAR
  6. Mar 10, 202610-Q EDGAR
  7. Mar 9, 20268-K EDGAR
  8. Feb 26, 202625-NSE EDGAR
  9. Feb 20, 20268-K EDGAR
  10. Feb 12, 2026DEF 14A EDGAR
  11. Jan 23, 2026SCHEDULE 13G EDGAR
  12. Jan 15, 20268-K EDGAR
  13. Jan 14, 2026424B4 EDGAR
  14. Jan 13, 2026EFFECT EDGAR
  15. Jan 13, 2026S-1MEF EDGAR
  16. Jan 13, 20268-A12B EDGAR
  17. Jan 13, 2026CERT EDGAR
  18. Jan 8, 2026CORRESP EDGAR
  19. Jan 8, 2026CORRESP EDGAR
  20. Jan 6, 2026CORRESP EDGAR

The 230 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 14, 2024Lustig MarcDirectorBuy902,935$2.22$2.0MForm 4
Dec 28, 2022Bondarenko JamiesonChairmanBuy28,000$4.58$128.2KForm 4
Dec 20, 2022Bondarenko JamiesonChairmanBuy22,000$5.35$117.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Dr. William V. WilliamsPresident and CEO70$711.7K$780.6K51
2025Mr. Gadi LevinCFO and Corporate Secretary54$485.4K$535.4K51
2025Dr. Giuseppe Del PrioreChief Medical Officer65$493.0K51
2025Dr. Miguel A. Lopez-LagoChief Scientific Officer56$447.5K51
2024Dr. William V. WilliamsPresident and CEO70$734.4K$1.1M51
2024Dr. Giuseppe Del PrioreChief Medical Officer65$540.3K$780.8K51
2024Mr. Gadi LevinCFO and Corporate Secretary54$443.0K$520.7K51
2024Dr. Miguel A. Lopez-LagoChief Scientific Officer56$357.7K$393.6K51

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cable Car Capital, LP216,821$702.5K0.0%No change
Sabby Management, LLC80,721$261.5K2.2%+6,806
Iridian Asset Management Llc/ct65,000$210.6K0.1%No change
UBS Group AG43,642$141.4K0.0%+32,101
Jane Street Group, LLC26,515$85.9K0.0%New
LuminArx Capital Management LP15,000$48.6K0.0%No change
National Bank Of Canada /fi/1,803$5.8K0.0%+1,001
Morgan Stanley1,033$3.3K0.0%−1,988
Federation des caisses Desjardins du Quebec450$1.4K0.0%−5
Royal Bank Of Canada289$1.0K0.0%+189
Allworth Financial LP100$3240.0%No change
Ssa Swiss Advisors Ag37$1210.0%New
Hrt Financial LP34,904$1130.0%New
Caitong International Asset Management Co., Ltd34$1100.0%+27
TD Waterhouse Canada Inc.19$660.0%No change
Group One Trading LLC16$520.0%No change
HHM Wealth Advisors, LLC6$200.0%No change
Wells Fargo & Company/mn1$30.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How BriaCell Therapeutics Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBriaCell Therapeutics Corp.1
  • CIK0001610820
  • Employer ID (EIN)47-10995995
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated inA15
  • Fiscal year endsJuly 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3Rd Floor, Bellevue Centre, 235-15Th Str, West Vancouver, A1 V7T 2X11
  • Phone(604) 921-18101
  • Shares outstanding8,699,787 as of Jun 9, 202612
  • Public float$94.5M as of Jan 31, 20255
  • AuditorMNP LLP, Mississauga, Canada PCAOB ID 1930; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJun 20, 20141
  • Filings323 in all: 8-K (65), 6-K (51), CORRESP (32), F-1/A (15), UPLOAD (14), SC 13G (13), 10-Q (12), SC 13G/A (11)1
    All 39 form types

    3 (10), EFFECT (9), 424B5 (8), SCHEDULE 13G (7), 424B4 (6), DEF 14A (5), SC 13D/A (5), 10-K (4), 4 (4), 424B3 (4), D (4), DRS (4), FWP (4), 8-A12B (3), CERT (3), DRSLTR (3), POS AM (3), S-1 (3), S-1/A (3), SCHEDULE 13G/A (3), F-1 (2), PRE 14A (2), S-1MEF (2), SC 13D (2), 25-NSE (1), 40-F (1), 40-F/A (1), DEFA14A (1), DEL AM (1), S-3 (1), S-8 (1)

  • Latest filingsAnnual report (10-K) Oct 16, 2025
    Quarterly report (10-Q) Jun 9, 2026
    Proxy statement (DEF 14A) Feb 12, 2026
    Latest 8-K (8-K) Jun 26, 2026

Securities registered for trading

ClassSymbolExchange
Common shares, no par valueBCTXNasdaq
Warrants to purchase common shares, no par valueBCTXWNasdaq
Warrants to purchase common shares, no par valueBCTXZNasdaq

From the cover page of the 10-K filed Oct 16, 2025 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks BriaCell Therapeutics Corp. names in Item 1A of its 10-K filed Oct 16, 2025: 43 risks under these headings, as written.5

  • Risks Related to Our Business
  • Pre-clinical studies and initial clinical trials are not necessarily predictive of future results
  • We are heavily reliant on third-parties to carry out a large portion of our business
  • Risks Related to Our Intellectual Property
  • We may not successfully develop, maintain and protect our proprietary products and technologies
  • We are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial damages or prohibit us from selling our product candidates
  • The steps we have taken to protect our intellectual property may not be adequate, which could have a material adverse effect on our ability to compete in the market
  • We may need to initiate lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive and, if we lose, could cause us to lose some of our intellectual property rights, which would harm our ability to compete in the market
  • We may be subject to damages resulting from claims that we or our employees or contractors have wrongfully used or disclosed alleged trade secrets of their former employers
  • If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • Risks Related to Regulations
The other 34 risks
  • Changes in legislation and regulations may affect our revenue and profitability
  • If we or our licensees are unable to obtain U.S., Canadian and/or foreign regulatory approval for our product candidates, we will be unable to commercialize our therapeutic candidates
  • If the third parties on which we rely to conduct our clinical trials and clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for, or commercialize, our product candidates
  • Modifications to our product candidates, or to any other product candidates that we may develop in the future, may require new regulatory clearances or approvals or may require us or our licensees, as applicable, to recall or cease marketing these therapeutic candidates until clearances are obtained
  • The results of our clinical trials may not support our product claims or may result in the discovery of adverse side effects
  • Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results
  • The pharmaceutical business is subject to increasing government price controls and other restrictions on pricing, reimbursement and access to drugs, which could adversely affect our future revenues and profitability
  • United States federal and state privacy laws, and equivalent laws of other nations, may increase our costs of operation and expose us to civil and criminal sanctions
  • If we fail to comply with the U.S. federal Anti-Kickback Statute and similar state and foreign country laws, we could be subject to criminal and civil penalties and exclusion from federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third country programs, which would have a material adverse effect on our business and results of operations
  • In both domestic and foreign markets, the development, formulation, manufacturing, packaging, labeling, handling, distribution, import, export, licensing, sale and storage of pharmaceuticals and medical devices are affected by a body of laws, governmental regulations, administrative determinations, including those by Health Canada and the FDA, court decisions and similar constraints.
  • We may not succeed in completing the development of our products, commercializing our products or generating significant revenues
  • Business related risks
  • There is substantial doubt about our ability to continue as a going concern
  • We have an unproven market for our product candidates
  • We are a pre-revenue clinical stage company
  • We may not succeed in adapting to and meeting the business needs associated with our anticipated growth
  • BriaPro may not generate revenue as expected
  • We are highly dependent on our key personnel
  • If the Company experiences a data security breach and confidential information is disclosed, the Company may be subject to penalties and experience negative publicity
  • A material breach in security relating to the Company’s information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation.
  • The Company’s international operations expose it and its representatives, agents and distributors to risks inherent to operating in foreign jurisdictions that could materially adversely affect its operations and financial position.
  • Risks Related to Our Securities
  • If we are not able to comply with the applicable continued listing requirements or standards of the TSX Exchange or Nasdaq, the TSX Exchange or Nasdaq could delist our common shares
  • Financial risk
  • We have a history of losses, may incur future losses and may not achieve profitability
  • We must obtain additional capital to continue our operations
  • Future issuance of our common shares could dilute the interests of existing shareholders
  • Short sellers may be manipulative and may drive down the market price of our common shares
  • We have a significant number of restricted share units, options and warrants outstanding, and while these options and warrants are outstanding, it may be more difficult to raise additional equity capital
  • Sales of a substantial number of our common shares in the public market by our existing shareholders could cause our share price to fall
  • We are an Emerging Growth Company, which may reduce the amount of information available to investors
  • We have never paid cash dividends on our capital stock and we do not anticipate paying any dividends in the foreseeable future. Consequently, any gains from an investment in our common shares will likely depend on whether the price of our Common shares increases, which may not occur
  • In the event a market develops for our common shares or Warrants, the market price of our common shares or Warrants may be volatile
  • If we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences as a result
  • If estimates of revenue, expenses, or capital or liquidity requirements change or are inaccurate, or if cash generated from operations is insufficient to satisfy liquidity requirements, the Company may arrange additional financings
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our shares, our share price and trading volume could decline
  • Certain Canadian legislation contains provisions that may have the effect of delaying or preventing a change in control
  • Because we are a corporation incorporated in British Columbia and some of our directors and officers are resident in Canada or other countries, it may be difficult for investors in the United States to enforce civil liabilities against us based solely upon the federal securities laws of the United States. Similarly, it may be difficult for Canadian investors to enforce civil liabilities against our directors and officers residing outside of Canada
  • Global economic uncertainty and financial market volatility caused by political instability, changes in international trade relationships and conflicts, such as the conflict between Russia and Ukraine and rising tensions in the Middle East, could make it more difficult for us to access financing and could adversely affect our business and operations.
  • We may be adversely affected by the effects of inflation.

Legal proceedings

We may be involved from time to time in ordinary litigation, negotiation, and settlement matters that will not have a material effect on our operations or finances. There are no material legal proceedings pending against the Company.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51